Bone Marrow Transplant Clinical Trials - PrECOG, LLC. Pre0905

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03836209

CONDITION(S): Acute Myeloid Leukemia - TRIAL: PrECOG, LLC. Pre0905 - Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation.

Drug

GilteritinibDrug: MidostaurinDrug: DaunorubicinDrug: Cytarabine

Trial Type

Interventional

Condition

Acute Myeloid Leukemia

Keywords

Acute Myeloid Leukemia | PrECOG